UBS lowered the firm’s price target on Sight Sciences (SGHT) to $11 from $12 and keeps a Buy rating on the shares. Results were largely in line with expectations, with strong performance in Dry Eye offset by weaker Surgical Glaucoma trends, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences Posts Q4 Growth, Issues 2026 Outlook
- Sight Sciences reports Q4 EPS (8c), consensus (14c)
- Sight Sciences sees FY26 revenue $82M-$88M, consensus $86.11M
- Underappreciated Growth in TearCare and OMNI Drives Buy Rating and $8 Target for Sight Sciences
- Sight Sciences price target raised to $8 from $6 at Stifel